

Introduction and overall state of play of the Accreditation and Designation Programme

Simon Oberst, Director of Quality and Accreditation

Jean-Benoît Burrion, Chair, A&D Board

11th June 2025 0845, Athens Oncology Days

The OECI Network



41

Comprehensive Cancer Centres

20

Cancer Centres

2

Comprehensive Cancer Networks

34

Centres in accreditation

=

97

Centres and Networks in our programme



22 centres with Peer Reviews conducted and planned for 2025



**ACCREDITATION
AND
DESIGNATION
PROGRAMME**

- | | |
|------------------------------------------------|------------------------------------------------|
| 1. Saint Savvas, Athens, Greece | 10. Lille Unicancer Centre, France |
| 2. Montpellier Unicancer Centre, France | 11. Cambridge CRUK Centre, UK * |
| 3. Rijnstate Hospital, Arnhem, The Netherlands | 12. Bordeaux Unicancer Centre, France |
| 4. The Christie, Manchester, UK * | 13. Turku University Hospital, Finland * |
| 5. ICO-HUB, Barcelona, Spain | 14. Institut Jules Bordet (HUB), Belgium * |
| 6. Caen Unicancer Centre, France * | 15. Riga East University Hospital, Latvia |
| 7. Aarhus University Hospital, Denmark | 16. Brescia Cancer Centre, Italy |
| 8. St Vincent's Hospital, Dublin, Ireland | 17. Nice Unicancer Centre, France |
| 9. Saint Joan de Reus Barcelona, Spain | 18. Copenhagen/Gemtofte Cancer Centre, Denmark |
| | 19. Clinic Barcelona, Spain |
| | 20. Akerhus Cancer Centre, Oslo, Norway |
| | 21. Mater Misericordiae, Dublin, Ireland |
| | 22. Hospital Jimenez Diaz, Madrid, Spain |

* *Reaccreditation*



10.30-10.45

CEREMONY FOR THE DELIVERY OF THE OECI A&D CERTIFICATES June 2024-June 2025

Giovanni Apolone and Jean-Benoît Burrion

Cancer Center Clinica Universidad de Navarra
Cancer Institute AP-HP. Nord - Université Paris Cité
Centre de lutte contre le cancer Eugène Marquis
Cork University Hospital/University College Cork
Erasmus MC Cancer Institute
Fundación Instituto Valenciano de Oncología
General Oncology Hospital of Athens "Saint Savvas"
Gustave Roussy
HSE West North West, University of Galway Cancer Centre
Institut Paoli Calmettes
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
IRCCS Ospedale San Raffaele (OSR)
Karolinska Comprehensive Cancer Center
Leuven Kankerinstituut (LKI)
Linköping Comprehensive Cancer Center
TAYS Cancer Centre Tampere University Hospital
Trinity St. James's Cancer Institute
Uppsala University Hospital

GENERAL ASSEMBLY ADMINISTRATIVE SESSION

23



New centres recently applied for 2024-25



**ACCREDITATION
AND
DESIGNATION
PROGRAMME**

1. Haukeland University Hospital, Bergen, Norway
2. Akershus University Hospital Cancer Centre, Nordbyhagen, Norway
3. Umeå Comprehensive Cancer Centre, Umea, Sweden
4. Landspítali - University Hospital, Reykjavík, Iceland
5. Paul Stradins Clinical University Hospital, Riga, Latvia
6. National Cancer Centre, Vilnius, Lithuania,
7. Copenhagen Comprehensive Cancer Center, Copenhagen, Denmark
8. Centre Antoine Lacassagne, Nice, France
9. Alliance Toulouse Cancer, Toulouse, France
10. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
11. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
12. 12 Octubre university hospital, Madrid, Spain
13. Hospital Clínico San Carlos, Madrid, Spain
14. King Hussein Cancer Center, Amman, Jordan
15. Instituto Nacional de Cancerología, Bogota, Colombia
16. AC Camargo Cancer Center, Sao Paulo, Brasil



- The last few years have seen big growth in France, Ireland and above all, Spain...
- Denmark, The Netherlands, and others...
- We are looking beyond Europe – e.g. Latin America
- Slow development in Central and Eastern Europe needs attention (Cost ? Readiness?)



Continuous OECD auditors' training courses


123

Active Auditors



- Chairs (Directors)
- Nurses / Nurse background
- Quality Managers
- Physicians
- Research background
- Other (pharmacy, psychologist)

Our Auditors



Our auditors are our front-line precious resource



Researchers and directors wanted!



Organisation of European Cancer Institutes - EEIG



The A&D Board

The A&D Board is responsible for the decision-making on Accreditation and Designation procedures and policies. It also decides on application approval, preliminary designation, decision go/no go peer review, certification and designation.



**Jean Benoit
Burrion**

Chair of the A&D Board



Mef Nilbert



Wim van Harten



Vanesa Gregorc



John V. Reynolds



Jorrit Enserink



**Eva Jolly-
Gustafsson**



Paulina Bravo



Peter Nagy



Claire Noonan



József Lövey

The A&D Accreditation Committee



Miguel Areia



Mary Fogarty



József Lövey



Marek Svoboda



Patricia Doherty



Fiona Harris



Mari-Leen Pärn



Mario de Bellis



Helen Varres



Stefania Grisanti



David Verger



Hişam Alahdab



Outi Nikunen

Organisation of European Cancer Institutes - EEIC



Our Management Unit

The A&D Co-ordinators play an important role throughout the whole process of the A&D programme, from the application by the centre until the approval of the final report and improvement action plan by the OEI A&D Board and the one-year follow-up.



Simon Oberst

Director of Quality and Accreditation



Hilde Dijcker van der Linden



Harriet Blaauwgeers




Jolanda van Hoeve



Wendy Dontje



Janneke Verloop



Marjet Docter



Roxana Plesoianu



Sylvia Blommestein



Willien Westerhuis

- CCI4EU (OECD coordinating): 55 partners: Capacity Building in Comprehensive Cancer Infrastructures (CCIs)
 - Full session tomorrow at 1400
- EU on QoL – 0845 tomorrow full session
- EU Net CCC – OECD HQ is not directly involved; some CCCs are
 - Message: The A&D Programme will continue to grow and be used
- JANE 1 and 2
- ECHoS 1 and 2 – Cancer Mission Hubs

Guidance Note on Requirements for Governance Structures of Cancer Centres which will comply with OECD Standards

Introduction

It is in particular to help define effective governance structures in University Hospitals that this Guidance Note is written, in order to fulfil OECl Standards.



MORE AT:
OECLEU/ACCREDITATION



Guidance

The Guidance which follows is intended to assist you in the development of your cancer centre. It will be your decision how to adopt this guidance.



ACCREDITATION AND DESIGNATION



Requirements in order to fulfil the Standards

- 1** To have established a clear description of the role, mandate and accountabilities of a (Comprehensive) Cancer Centre Board, which encompasses all aspects of the cancer care pathway and all forms of cancer research. It should define how the (University) Hospital(s) and the University(ties) work together in cancer.

We provide in an appendix three possible models of a Cancer Centre Board in the context of a University Hospital(s) and a partner University (or Universities) and/or research institutes, which would fulfil OECD Standards.

The balance of clinical and scientific representation on the main (Comprehensive) Cancer Centre Board will differ according to context. But the key to the whole is the integration of clinical and research leadership in cancer in a single cancer-specific Board.

Model 1

The leadership of the (Comprehensive) Cancer Centre Board predominantly lies with senior Clinical leadership, but it is vital that key leaders of the cancer research community are also represented.

Model 2
(less common)

The leadership of the (Comprehensive) Cancer Centre Board predominantly lies with the research leadership, and it is vital that key leaders of the clinical cancer research community are also represented.

Model 3

This model has a Clinical Cancer Operational Board for the hospital(s), a Cancer Research/Teaching Board, and an overarching (Comprehensive) Cancer Centre Board bringing the key representatives of the other Boards together.





- The strengths of the accredited centres have been documented in the audit reports
- From these, 22 Excellent Practices in many different domains of care have been documented from around our centres
- The sharing of this material for the benefit of the OEI community is part of the vision and mission of the OEI A&D Programme.

Excellent Practices – we are
doing a new round in 2025-26

Planning the future



1. Expanding the OECD quality and A&D **community** (within Europe, and beyond)
 - ✓ Our first peer reviews in Latin America
2. Creating more of a sense of community: **spreading excellent practices; offering benchmarking**; proposing support
 - ✓ Second round of excellent practices next year
3. Developing a **'toolbox'** for Centres' development and accreditation – next slide
4. Developing Capacity Building capabilities (CCI4EU)
5. The roll-out of **Network** accreditations following the ONCOZON pilot and applying the principles in SE; NL; FL; IR; FR; IT.
6. Continuing to build ties with ASCO, NCCN and NCI in the **United States** to boost the international recognition of our programme.
7. Publishing a new paper in a **scientific journal** analysing the results of our centres
8. Developing a **paediatric** module for our Standards



- A collection of tools to enable Centres to develop structures and processes to grow, improve, and fulfil OECD Accreditation Standards.
 1. Governance documents
 2. Strategy documents (Centre and Research)
 3. Annual reports
 4. Patient pathway documents and templates
 5. MDT's Terms of Reference
 6. Dashboards
 7. TO BE COMPLETED

- ❖ We want to develop and improve what is distinctive about our quality and accreditation programme:
 - We believe in peer reviews, not technical audits
 - Our auditors are all professionals in Cancer Centres from day to day
 - Our programme is voluntary, not regulatory
 - We are enabling, not controlling
 - We are scalable and adaptable: we stay up to date
 - We can order our affairs and programme as our member experts and scientific findings demonstrate are best standards and practices
 - We want to be an effective community of practice where we enable each centre to improve, develop and learn from each other.

Thank you for your attention

